Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy

Improvements in the last decade in understanding the molecular mechanisms underlying acute myeloid leukemia (AML) have emphasized that treatment regimens should be personalized with agents that can selectively target genetic abnormalities if present. Neomorphic mutations in isoform 1 of isocitrate d...

Descripción completa

Detalles Bibliográficos
Autores principales: Nassereddine, Samah, Lap, Coen J, Tabbara, Imad A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314316/
https://www.ncbi.nlm.nih.gov/pubmed/30643428
http://dx.doi.org/10.2147/OTT.S182443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314316/
https://www.ncbi.nlm.nih.gov/pubmed/30643428
http://dx.doi.org/10.2147/OTT.S182443

Ejemplares similares